Sensei Biotherapeutics Begins Trial for New Breast Cancer Treatment
Sensei Biotherapeutics has dosed the first patient in a Phase 1b/2 trial of PIKTOR, an investigational treatment for HR+/HER2- advanced breast cancer. PIKTOR is an all-oral combination of serabelisib and sapanisertib, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, which is often altered in HR+/HER2- cases. The trial, known as Study FTH-PIK-101, is a multi-center, dose-escalation study evaluating the safety and efficacy of PIKTOR in combination with other anticancer therapies. This trial follows a previous Phase 1b study where PIKTOR showed promising results in patients with advanced breast, endometrial, and ovarian tumors. 
